Key Takeaways
  • The study is real and well run. A research compound called 991, which switches on the energy-sensing enzyme AMPK directly, extended lifespan in fission yeast, roundworms and fruit flies, "in some cases by more than 25%" (MRC Laboratory of Medical Sciences release on the Aging Cell paper, 30 September 2026)
  • No mouse lifespan test yet. Mice were dosed only for a protein-profile analysis; a mouse lifespan study is the stated next step. Write-ups saying the drug extended lifespan in mice, or naming zebrafish, are wrong
  • The worm-to-mouse record is poor. In the NIA's Interventions Testing Program, resveratrol, green tea extract, curcumin, fish oil and metformin alone all failed to extend mouse lifespan. Rapamycin and acarbose did, by up to 26% and 22% of median lifespan
  • You already own an AMPK activator. Exercise activates AMPK in human muscle. Metformin does so indirectly, and its longevity trial has never launched; calorie restriction improved risk factors in a two-year human trial but has no lifespan data
  • Don't buy anything off the back of this. Compound 991 has never been given to a human. One direct AMPK activator, MK-8722, caused heart-muscle thickening in rodents and monkeys. No supplement sold as an "AMPK activator" has been shown to extend human life

You may have seen the headline this week: scientists extend lifespan by a quarter with a single drug. The study behind it is genuine, it comes from a serious lab, and the result is interesting. It's also in yeast, worms and flies. That's not a put-down. It's the whole story, and it's worth understanding why.

Here's what the paper found, why "it worked in flies" has so often meant "it didn't work in mice", what already activates the same enzyme in your own body, and what to do with the news.

>25%
Lifespan extension "in some cases" from direct AMPK activation, in yeast, worms and flies. Mouse lifespan: not yet tested (MRC Laboratory of Medical Sciences, September 2026)
Part one · The study

Yeast, Worms, Flies, and (So Far) No Mouse Lifespan

Evidence: Strong in model organisms — no mammalian lifespan data yet

The paper, "Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies", was published in Aging Cell on 30 September 2026 (press release date) by a team led from the MRC Laboratory of Medical Sciences and Imperial College London, with the University of Cologne and others (Dos Santos et al., Aging Cell 2026; UKRI press release).

AMPK, AMP-activated protein kinase, is an enzyme in our cells that tracks how much energy the cell has. When energy runs low it shuts down expensive building projects like protein synthesis and fat storage and turns on the breakdown of fat and sugar for fuel. In the words of Dr Helena Cochemé, one of the lead authors: "AMPK is effectively the body's equivalent to the 'energy saving mode' on a mobile phone."

The idea that switching on AMPK might slow ageing isn't new. What's new here is how the switch was flipped. Metformin and semaglutide activate AMPK indirectly, as a side-effect of what they do elsewhere, which makes it hard to say whether AMPK is responsible for any benefit. Compound 991 acts on AMPK directly. The team gave it to three distantly related organisms: the fission yeast S. pombe, the roundworm C. elegans and the fruit fly Drosophila. Lifespan went up in all three, "in some cases by more than 25%". Cochemé's summary: "The fact that we can extend lifespan in yeast, worms and flies is very exciting."

Two things the headlines tend to drop. First, the per-species numbers: the press release gives only "more than 25% in some cases", and the abstract gives no per-species figures and the full text was not accessible to us, so we won't invent precision the release doesn't offer. Second, the species list. If the version you read said it extended lifespan in mice, or mentioned zebrafish, it was wrong. The paper's title names yeast, worms and flies; mice were treated only for a protein-profile analysis, and a mouse lifespan study is what comes next. Professor David Carling, a co-author: "Now that we have very solid, convincing evidence from the laboratory model organisms, the next step will be to show that we can also improve health and extend lifespan in mice."

The headlineAnti-ageing drug extends life by 25%.
What the paper shows (per its press release)A direct AMPK activator extended lifespan in yeast, worms and flies, by over 25% in some cases. No mouse lifespan data, no humans. The authors themselves say human anti-ageing trials are "still a long way" off.

That last quote deserves its full context. Professor Filipe Cabreiro, another of the senior authors: "The field is still a long way from anti-ageing clinical trials in humans." The researchers are being careful. The question is whether the rest of us will be.

Part two · The track record

From Worm to Mouse, Most Drugs Fail

Evidence: Strong — multi-site randomised mouse trials

Why does "it worked in flies" carry so little weight on its own? Because we have an unusually good scorecard. The US National Institute on Aging runs the Interventions Testing Program (ITP), which feeds candidate compounds to genetically diverse mice at three independent labs, with enough animals in each group to detect modest effects. The same fly-and-worm favourites that fill supplement shelves have been through it.

The results are sobering. Resveratrol, green tea extract and curcumin, each fed from four months of age, produced no significant change in the lifespan of male or female mice (Strong et al., J Gerontol A 2013). Fish oil didn't extend lifespan either, and nor did metformin on its own at 0.1% of the diet (Strong et al., Aging Cell 2016). Metformin is worth pausing on, because it extends lifespan in worms and had the same "AMPK activator" billing. In C. elegans it works through the worm's bacterial food: metformin "increases or decreases worm lifespan, depending on E. coli strain metformin sensitivity and glucose concentration" (Cabreiro et al., Cell 2013). Cabreiro, incidentally, is a senior author on the new paper, which is one reason to expect the mouse study will actually be done.

Figure 1 · Three species, three levels of evidence

Worms and flies vs mice vs humans: what's actually been shown

InterventionWorms / fliesMiceHumans
Compound 991 direct AMPK activatorLifespan up in yeast, worms and flies, >25% in some cases Aging Cell 2026Dosed for proteomics only; 'pro-longevity' protein profile, no lifespan test stated next stepNever given to a person
Metformin indirect AMPK activatorExtends worm lifespan, but depends on the worms' bacteria and glucose Cell 2013No significant extension alone at 0.1% of diet ITP, Aging Cell 2016No lifespan trial. TAME planned (3,000 people, 65–79, six years) but not launched; earlier "outlive non-diabetics" finding reversed in Danish registers Int J Epidemiol 2022
Rapamycin mTOR inhibitor—Median lifespan +23% males, +26% females at 42 ppm from 9 months; a lower dose works even when started at 20 months ITP, Aging Cell 2014; Nature 2009No lifespan data
Resveratrol—No significant effect in either sex ITP, J Gerontol A 2013No lifespan data
Calorie restriction——Two years at ~12% below usual intake: 7.5 kg lost, LDL, blood pressure, CRP and insulin sensitivity improved. No lifespan data CALERIE-2, Lancet Diabetes Endocrinol 2019
Exercise——Activates AMPK in human skeletal muscle Biochem J 2009; the only AMPK route with decades of human outcome data

"—" means we didn't verify a primary source for that cell, not that no study exists. ITP = NIA Interventions Testing Program, which tests compounds in genetically heterogeneous mice at three sites. Sources numbered in the list at the end.

It's not all failure, and the exceptions matter because they show what a real hit looks like. Rapamycin, which blocks the mTOR pathway, is the ITP's clearest success: fed from 600 days of age, about 20 months, it raised the age at which 90% of mice had died by 14% in females and 9% in males (Harrison et al., Nature 2009). At a dose three times higher, median lifespan rose by 23% in males and 26% in females (Miller et al., Aging Cell 2014). Acarbose, a diabetes drug that slows starch digestion, increased male median lifespan by 22% but female median lifespan by only 5% (Harrison et al., Aging Cell 2014). 17α-estradiol, a weak oestrogen, added 12% to male median lifespan at the first dose tested and did nothing for females; at three times the dose it "robustly extended both median and maximal lifespan, but still only in males" (Strong 2016).

Figure 2 · NIA Interventions Testing Program

Change in median lifespan of mice, by compound and sex

Rapamycin 42 ppm (3× the 2009 dose) +23% ♂ +26% ♀ Acarbose 1,000 ppm, from 4 months +22% ♂ +5% ♀ 17α-estradiol 4.8 ppm, from 10 months +12% ♂ no significant change ♀ Metformin alone 0.1% of diet no significant change (both sexes pooled in the abstract) Resveratrol from 4 months no significant change ♂ no significant change ♀ Males Females Bar length = % change in median lifespan vs controls

Genetically heterogeneous (UM-HET3) mice, pooled across three sites. Rapamycin: Miller et al. 2014. Acarbose and 17α-estradiol: Harrison et al. 2014 (acarbose females +5%, P = 0.01). Metformin: Strong et al. 2016. Resveratrol: Strong et al. 2013. Green tea extract, curcumin and fish oil also showed no significant lifespan effect in the same programme and are omitted for space.

Notice the pattern in the hits. Effects differ by sex, sometimes sharply, and depend on dose. And the compounds that worked in mice weren't the ones with the loudest fly-and-worm stories. None of this says compound 991 will fail in mice. It says the mouse study is the test, not a formality.

Part three · AMPK in humans already

You Already Have an AMPK Activator

Evidence: Strong for exercise · Moderate for calorie restriction · Weak for metformin

The odd thing about the excitement is that AMPK is not an exotic target waiting for a drug. Three things people already do switch it on.

Exercise. AMPK responds to the ratio of spent to available energy in a cell, and nothing changes that ratio in muscle like contraction. A review in the Biochemical Journal puts it plainly: during exercise AMPK "is activated in skeletal muscle in humans" (Richter & Ruderman, Biochem J 2009). This is the one AMPK activator with a long human track record attached, not because anyone ran an AMPK trial but because exercise has been studied for mortality for decades. If a reader wants a dose, our guide to the Norwegian 4x4 covers the protocol with the best VO2 max evidence.

Not overeating. Calorie restriction is the oldest lifespan intervention in lab animals and lowers the energy supply AMPK monitors. In humans we have one serious trial: CALERIE-2, which randomised 218 healthy non-obese adults aged 21 to 50 to two years of a 25% calorie cut or their usual diet. The restriction group managed an average cut of 11.9%, not 25%, and lost a sustained 7.5 kg. Their LDL cholesterol and blood pressure fell significantly from baseline, and C-reactive protein, insulin sensitivity and metabolic-syndrome score improved relative to controls (Kraus et al., Lancet Diabetes Endocrinol 2019). That's cardiometabolic risk, not lifespan; a two-year trial in 40-year-olds can't measure lifespan. But it's human, randomised and consistent.

Metformin. The diabetes drug activates AMPK indirectly, which is exactly the problem the new study was designed to get around. Its longevity reputation rests on a widely quoted observational finding that people with diabetes on metformin outlived people without diabetes. A 2022 Danish register study set out to reproduce that and found the reverse: starting metformin alone was associated with higher all-cause mortality than people with no diabetes diagnosis, with an incidence rate ratio of 1.32 (95% CI 1.16–1.50) after adjusting for comorbidities and social factors; in twin pairs discordant for metformin the adjusted ratio was 1.64, and the authors concluded that metformin "was not associated with survival equal or superior to that of the general population without diabetes" (Keys et al., Int J Epidemiol 2022). The trial meant to settle the question, TAME (Targeting Aging with Metformin), would enrol 3,000 people aged 65 to 79 for six years at 14 sites. As of this writing, the American Federation for Aging Research's own page still describes it as a trial to be launched once donors are found (AFAR). It has not reported anything because it hasn't started.

Part four · Direct activators in people

The Drugs That Are Already in Humans

Evidence: Early — short phase 2 trials, no long-term safety data

Carling notes that "Direct AMPK activators have already been used safely in clinical trials for the treatment of specific metabolic diseases." That's true, and it's worth seeing exactly what it rests on, because it's thinner than it sounds.

Figure 3 · Direct AMPK activators and what's known

Three compounds, three very different results

CompoundTested inFindingSafety signal
O304Mice, rats, dogs; 65 people with type 2 diabetes on metformin, 28 days phase 2aFasting glucose −0.60 mmol/L vs −0.10 on placebo in a post-hoc subgroup of 49; systolic BP −5.8 mmHg, diastolic −3.8No increase in heart weight in mice or rats; no ECG abnormality or change in heart muscle mass in the 28-day trial JCI Insight 2018
PXL770121 people with fatty liver disease, 12 weeks phase 2, NCT03763877Liver fat −14.3% (250 mg twice daily) and −14.7% (500 mg daily) vs −1.1% on placebo; neither reached P < 0.053 serious adverse events in the two higher-dose arms, 0 on placebo; no long-term data ClinicalTrials.gov
MK-8722Rodents and rhesus monkeys, including diabetic monkeysRobust, insulin-independent glucose uptake in muscle; better glycaemia with no hypoglycaemiaCardiac hypertrophy and increased heart glycogen, "without apparent functional sequelae" Science 2017
Compound 991Yeast, worms, flies; mice (proteomics only)Lifespan extended, >25% in some casesNot reported in the press release; no mammalian safety or lifespan data

O304: Steneberg et al. 2018. PXL770: ClinicalTrials.gov results posted October 2021, least-squares mean relative change in liver fat by MRI-PDFF. MK-8722: Myers et al. 2017. None of these trials lasted longer than 12 weeks, and none measured lifespan.

So the human experience with direct AMPK activators amounts to a 28-day trial in 65 people and a 12-week trial in 121 people, in disease, with reassuring but short-term safety. Set against that is MK-8722, a direct activator of all twelve mammalian AMPK complexes, which did what it was meant to do for blood sugar in monkeys and also thickened their heart muscle (Myers et al., Science 2017). The findings aren't contradictory; different compounds behave differently. But they're a reminder that AMPK has many jobs, the heart's included, and that "safe for 28 days" and "safe to take for decades to age slower" are not the same claim. Nobody has dosed healthy people with a direct activator for years, and it isn't in the plan.

Part five · What to do

What to Do With This News

Here's the honest ledger. A direct AMPK activator extends lifespan in three short-lived laboratory species. The right next experiment is in mice, which the authors plan to run. The historical odds for a compound at this stage are not good, the human safety record for this class is short, and compound 991 has never been in a person. None of that should change what you do this week, except to notice that the enzyme in the headline is one you can already switch on.

And if you want to know whether any of it is working for you, biological-age tests are softer than they look; blood pressure, waist, lipids and fitness are still the numbers to track with your doctor.

Frequently Asked Questions

Did the new AMPK drug extend lifespan in mice?
No. The Aging Cell study published on 30 September 2026 (press release date) tested compound 991 in fission yeast, the roundworm C. elegans and the fruit fly Drosophila. Mice were given the compound too, but only for a proteomic (protein-profile) analysis, which the authors describe as 'pro-longevity'. No mouse lifespan study has been done; that is the stated next step. Write-ups that say the drug extended lifespan in mice, or that list zebrafish, are wrong.
How much longer did the animals live?
The paper's abstract reports lifespan extension in all three organisms; the MRC LMS release says 'in some cases by more than 25%'. Separate figures for yeast, worms and flies were not given in the release, the abstract gives no per-species figures and the full text was not accessible to us at the time of writing, so we don't quote more precise numbers.
Can I buy an AMPK activator supplement?
Products are sold with that label, but compound 991 is a research chemical that has never been given to a person, and nothing sold as an AMPK activator supplement has been shown to extend human lifespan. The record of worm and fly results carrying over to mice is poor: in the NIA Interventions Testing Program, resveratrol, green tea extract, curcumin, fish oil and metformin alone all failed to extend mouse lifespan.
What activates AMPK in people today?
Exercise. AMPK is activated in human skeletal muscle during exercise, which is the one way to switch it on that has decades of human outcome data behind it. Metformin activates it indirectly, and calorie restriction lowers the energy supply AMPK responds to. Of these, only exercise has human evidence for living longer; metformin's longevity trial (TAME) has not launched, and calorie restriction's human trial measured risk factors, not lifespan.
Are direct AMPK activators safe in humans?
Two have been given to people in short trials: O304 for 28 days in 65 people with type 2 diabetes, and PXL770 for 12 weeks in 121 people with fatty liver disease. Both were reported by their sponsors as well tolerated; in the PXL770 trial three participants on the higher doses had serious adverse events (including atrial fibrillation), none on placebo. But a different direct activator, MK-8722, caused cardiac hypertrophy (heart muscle thickening) in rodents and rhesus monkeys, so safety has to be shown for each compound, and no activator has been tested for years, which is what an anti-ageing use would require.
The Bottom Line

A good fly result is still a fly result.

Compound 991 switched on AMPK directly and three distantly related organisms lived longer, in some cases by more than a quarter. That's a real finding from a careful lab, and the mouse study it points to is worth waiting for. But the same programme that would test it has watched resveratrol, curcumin, green tea, fish oil and metformin all fail to extend mouse lifespan, and the only direct AMPK activators that have touched humans did so for weeks, not decades.

The enzyme in the headline is one you already control. Hard exercise activates it in your muscle; not overeating keeps the energy signal honest. Do those, skip the supplement aisle, and talk to your doctor before taking any drug for a disease you don't have.

Sources

  1. Dos Santos et al. Direct Pharmacological Activation of AMPK Extends Lifespan in Yeast, Worms and Flies. Aging Cell 2026;25(10):e70721, doi 10.1111/acel.70721 (press releases 30 September 2026). The full text was not accessible to us at the time of writing; study details are taken from the abstract (PubMed 42810392) and the institutional releases below.
  2. UK Research and Innovation. Experts extend lives of animals by activating 'energy saver' mode. 30 September 2026.
  3. MRC Laboratory of Medical Sciences. Experts significantly extend lives of animals by activating 'energy saver' mode. 30 September 2026.
  4. Strong R, Miller RA, Astle CM, et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2013;68(1):6–16.
  5. Strong R, Miller RA, Antebi A, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell 2016;15(5):872–884.
  6. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392–395.
  7. Miller RA, Harrison DE, Astle CM, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 2014;13(3):468–477.
  8. Harrison DE, Strong R, Allison DB, et al. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 2014;13(2):273–282.
  9. Cabreiro F, Au C, Leung K-Y, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013;153(1):228–239.
  10. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 2009;418(2):261–275.
  11. Kraus WE, Bhapkar M, Huffman KM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7(9):673–683.
  12. Keys MT, Thinggaard M, Larsen LA, et al. Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study. Int J Epidemiol 2022;51(6):1886–1898.
  13. American Federation for Aging Research. The TAME Trial. Accessed 8 October 2026.
  14. Steneberg P, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight 2018;3(12):e99114.
  15. ClinicalTrials.gov. A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD (NCT03763877). Results posted 28 October 2021.
  16. Myers RW, Guan H-P, Ehrhart J, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 2017;357(6350):507–511.